Loading...
Loading...
YMAB| Name | Value |
|---|---|
| Revenues | 18.5M |
| Cost of Revenue | 2.2M |
| Gross Profit | 16.2M |
| Operating Expense | 24.8M |
| Operating I/L | -8.6M |
| Other Income/Expense | 1.9M |
| Interest Income | 1.9M |
| Pretax | -6.7M |
| Income Tax Expense | 0.3M |
| Net Income/Loss | -7.0M |
Y-mAbs Therapeutics, Inc. is a biopharmaceutical company specializing in the development and commercialization of novel antibody-based therapeutic products for cancer treatment. Its flagship product, DANYELZA, is a monoclonal antibody used in combination with granulocyte-macrophage colony-stimulating factor for pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also advancing other antibody-based therapies, including GD2-GD3 vaccine and Omburtamab, targeting various forms of neuroblastoma and other B7-H3 positive tumors. Additionally, Y-mAbs is developing Nivatrotamab for small cell lung cancer and Lu-omburtamab-DTPA for medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors.
